Protagonist Therapeutics (PTGX) Operating Income (2015 - 2026)
Protagonist Therapeutics (PTGX) reported Operating Income of -$3.6 million for Q1 2026, up 81.11% on a YoY basis from -$2.0 million in Q1 2025, and up 92.76% sequentially from -$50.4 million in Q4 2025.
Protagonist Therapeutics (PTGX) Operating Income (2015 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 12 years of Operating Income data on file, last reported at -$3.6 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income rose 81.11% year-over-year to -$3.6 million; the trailing twelve-month figure through Mar 2026 stood at -$142.5 million (down 623.31% YoY), and the FY2025 full-year result was -$158.1 million, down 162.54% from the prior year.
- Operating Income advanced to -$3.6 million in Q1 2026, from -$50.4 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $206.3 million in Q1 2024 to a low of -$50.4 million in Q4 2025.
- A 5-year average of -$7.9 million and a median of -$36.5 million in 2022 frame the typical range for Operating Income.
- Across the five-year window, Operating Income soared 672.75% in 2024 and slumped 139.72% in 2025, its largest moves.
- Tracing PTGX's Operating Income over 5 years: stood at -$36.5 million in 2022, then surged by 163.12% to $23.0 million in 2023, then surged by 450.05% to $126.8 million in 2024, then tumbled by 139.72% to -$50.4 million in 2025, then jumped by 92.76% to -$3.6 million in 2026.
- Business Quant data shows PTGX's Operating Income at -$3.6 million in Q1 2026, -$50.4 million in Q4 2025, and -$46.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | -3.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.65 Mn |
| Dec 31, 2025 | -50.36 Mn |
| Sep 30, 2025 | -46.42 Mn |
| Jun 30, 2025 | -42.04 Mn |
| Mar 31, 2025 | -19.31 Mn |
| Dec 31, 2024 | 126.78 Mn |
| Sep 30, 2024 | -41.45 Mn |
| Jun 30, 2024 | -38.79 Mn |
| Mar 31, 2024 | 206.31 Mn |
| Dec 31, 2023 | 23.05 Mn |
| Sep 30, 2023 | -38.33 Mn |
| Jun 30, 2023 | -42.35 Mn |
| Mar 31, 2023 | -36.02 Mn |
| Dec 31, 2022 | -36.52 Mn |
| Sep 30, 2022 | -32.30 Mn |
| Jun 30, 2022 | -41.44 Mn |
| Mar 31, 2022 | -21.11 Mn |
| Dec 31, 2021 | -37.02 Mn |
| Sep 30, 2021 | -33.93 Mn |
| Jun 30, 2021 | -30.88 Mn |